SINTX Technologies reported a 199% year-over-year increase in second-quarter 2026 revenue as the advanced ceramics and medical technology company expands commercialization of its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System and pursues additional medical and industrial applications for its silicon nitride technology.
Q2 revenue reached approximately $450,000, according to the company’s reported results surfaced in the attached filing summary. The company reported a net loss of approximately $2.71 million during the quarter as it continued investing in commercialization, product development and manufacturing capabilities.
A major part of SINTX’s near-term commercial strategy centers on the SiNAPTIC Foot & Ankle Osteotomy Wedge System, an FDA-cleared product designed for reconstructive surgery. The company is working to expand its distributor network and drive broader market adoption of the system.
The SiNAPTIC platform builds on SINTX’s broader expertise in silicon nitride, a proprietary biomaterial that the company is developing for medical and non-medical applications. SINTX’s business also encompasses medical device technologies, contract manufacturing and other advanced ceramics opportunities.
Commercial activity is also extending beyond the company’s orthopedic products. SINTX referenced industrial purchase orders with anticipated shipments and associated revenue recognition expected during the third and fourth quarters of 2026. The company is pursuing additional commercial applications for its advanced manufacturing platform as it seeks to diversify its sources of revenue.
SINTX’s first-half activity also included expanded commercialization, new orders and approximately $5 million of capital raised to support growth initiatives, according to the earnings-related information included in the attached TradingView document.
Another potentially significant part of the company’s pipeline is its development of patient-specific and custom implants. SINTX is advancing silicon nitride/PEEK implant technology and evaluating opportunities to expand its material platform into additional medical applications.
The company’s research pipeline includes a 3D-printed silicon nitride porous PEEK composite spinal cage program supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award R44AR083836. SINTX is conducting research and development activities that could generate preliminary data for potential licensing or strategic partners.
Alongside organic commercialization, SINTX is evaluating a broad range of strategic opportunities, including commercial partnerships, licensing arrangements, strategic investments, acquisitions and divestitures. These efforts could provide additional pathways for monetizing its silicon nitride intellectual property and advanced manufacturing capabilities.
The company’s growth initiatives remain subject to significant financial constraints. SINTX identifies limited liquidity, a history of operating losses and the need to obtain additional financing among its material risks. The company also notes potential dilution from future equity financing and substantial doubt regarding its ability to continue as a going concern.
The second-quarter revenue increase nevertheless represents an early indication that SINTX’s commercialization efforts are beginning to translate into sales. The next phase of the company’s strategy will depend on continued adoption of the SiNAPTIC Foot & Ankle system, execution on industrial purchase orders, advancement of its NIH-supported spinal implant program and its ability to secure sufficient capital to support those initiatives.
